Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by StockNews.com

StockNews.com began coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a report published on Wednesday morning. The firm issued a hold rating on the stock.

A number of other research analysts also recently issued reports on the stock. HC Wainwright reduced their price target on shares of Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Brookline Capital Management restated a “hold” rating on shares of Oncternal Therapeutics in a research report on Thursday, September 12th. Northland Capmk lowered shares of Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 12th. Finally, Northland Securities reissued a “market perform” rating and set a $2.00 target price on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, Oncternal Therapeutics currently has an average rating of “Hold” and a consensus target price of $20.00.

Oncternal Therapeutics Trading Down 7.7 %

Oncternal Therapeutics stock opened at $0.69 on Wednesday. Oncternal Therapeutics has a 52 week low of $0.62 and a 52 week high of $13.14. The stock has a market cap of $2.04 million, a P/E ratio of -0.06 and a beta of 1.33. The stock has a 50 day moving average of $1.29 and a 200-day moving average of $4.60.

Institutional Trading of Oncternal Therapeutics

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC purchased a new stake in Oncternal Therapeutics, Inc. (NASDAQ:ONCT) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned 0.84% of Oncternal Therapeutics as of its most recent SEC filing. Institutional investors own 16.05% of the company’s stock.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.